<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        Most common adverse reactions (incidence ≥ 10%) are oiliness/peeling, dryness and erythema at the application site (6).<BR><BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Clinical Studies Experience<BR><BR>                     <BR>                        Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<BR><BR>                        Serious adverse reactions reported in patients treated with ACZONE<BR>                           ® Gel, 5%, during clinical trials included but were not limited to the following:<BR><BR>                        <BR>                           Nervous system/Psychiatric – Suicide attempt, tonic clonic movements.<BR><BR>                           Gastrointestinal – Abdominal pain, severe vomiting, pancreatitis.<BR><BR>                           Other – Severe pharyngitis<BR><BR>                        <BR>                        In the clinical trials, a total of 12 out of 4032 patients were reported to have depression (3 of 1660 treated with vehicle and 9 of 2372 treated with ACZONE<BR>                           ® Gel, 5%). Psychosis was reported in 2 of 2372 patients treated with ACZONE<BR>                           ® Gel, 5%, and in 0 of 1660 patients treated with vehicle.<BR><BR>                        Combined contact sensitization/irritation studies with ACZONE<BR>                           ® Gel, 5%, in 253 healthy subjects resulted in at least 3 subjects with moderate erythema. ACZONE<BR>                           ® Gel, 5%, did not induce phototoxicity or photoallergy in human dermal safety studies.<BR><BR>                        <BR>                           ACZONE<BR>                           ® Gel, 5%, was evaluated for 12 weeks in four controlled studies for local cutaneous events in 1819 patients. The most common events reported from these studies include oiliness/peeling, dryness, and erythema. These data are shown by severity in Table 1 below.<BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t1" width="100%"><BR>                           <caption>Table 1 &#8211; Application Site Adverse Reactions by Maximum Severity<BR></caption><BR>                           <col width="29.529%" align="left"/><BR>                           <col width="11.571%" align="left"/><BR>                           <col width="12.614%" align="left"/><BR>                           <col width="11.571%" align="left"/><BR>                           <col width="9.471%" align="left"/><BR>                           <col width="13.671%" align="left"/><BR>                           <col width="11.571%" align="left"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                 <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                    <content styleCode="bold">ACZONE</content><BR>                                    <sup>&#174;</sup><BR>                                    <br/>(N=1819)<BR></td><BR>                                 <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule">Vehicle<br/>(N=1660)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Event<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Mild<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Moderate<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Severe<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Mild<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Moderate<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">Severe<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Erythema<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">5%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">9%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dryness<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">14%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">3%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">14%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Oiliness/Peeling<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">13%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">15%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6%<BR></td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">&lt;1%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>The adverse reactions occurring in at least 1% of patients in either arm in the four vehicle controlled studies are presented in Table 2.<BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t2" width="100%"><BR>                           <caption>Table 2 &#8211; Adverse Reactions Occurring in at Least 1% of Patients<BR></caption><BR>                           <col width="59.433%" align="left"/><BR>                           <col width="21.833%" align="left"/><BR>                           <col width="18.733%" align="left"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="3" align="left" valign="top"><BR>                                    <paragraph styleCode="footnote">NOS = Not otherwise specified<BR></paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                    <content styleCode="bold">ACZONE</content><BR>                                    <sup>&#174;</sup><BR>                                    <br/>N=1819<BR></td><BR>                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">Vehicle<br/>N=1660<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Reaction NOS<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">18%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">20%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Dryness<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">16%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">17%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Erythema<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">13%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">14%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Burning<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Application Site Pruritus<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pyrexia<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nasopharyngitis<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">5%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">6%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper Respiratory Tract Inf. NOS<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">3%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sinusitis NOS<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Influenza<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pharyngitis<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cough<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">2%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Joint Sprain<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">1%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache NOS<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">4%<BR></td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule">4%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>One patient treated with ACZONE<BR>                           ® Gel in the clinical trials had facial swelling which led to discontinuation of medication.<BR><BR>                        In addition, 486 patients were evaluated in a 12 month safety study. The adverse event profile in this study was consistent with that observed in the vehicle-controlled studies.<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2 Experience with Oral Use of Dapsone<BR><BR>                     <BR>                        Although not observed in the clinical trials with ACZONE<BR>                           ® Gel (topical dapsone) serious adverse reactions have been reported with oral use of dapsone, including agranulocytosis, hemolytic anemia, peripheral neuropathy (motor loss and muscle weakness), and skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria).<BR><BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>